Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Organon & Co. Common Stock (OGN) vs IAC/Interactivecorp (PPLI) Price & Performance

Organon & Co. Common StockTrade
IAC/InteractivecorpTrade

Price performance (Past 24H)

Key statistics

Organon & Co. Common Stock vs IAC/Interactivecorp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while IAC/Interactivecorp trades at $40.57 (market cap $3.04B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and IAC/Interactivecorp for 80 Days on average.

OGNPPLI
Market Cap
$3.62B$3.04B
Volume
2,892,999686,384
Sector
HealthMedia
52-Week High
$13.81$47.62
52-Week Low
$5.70$31.52
Typical Hold Time
0 Days80 Days
Enterprise Value
$11.04B$3.52B
Dividend Yield
0.58%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Organon & Co. Common Stock

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

IAC/Interactivecorp

PPLI trades at $40.56, down 0.73% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $104.03M in 2025 despite strong gross margins of 66.35%, with valuation metrics appearing attractive at P/E of 6.91 and P/B of 0.6. Recent MGM acquisition speculation has driven significant volatility, with shares surging 11.3% on takeover rumors according to Zacks Investment Research on September 28, 2026.

The outlook remains speculative with 71% analyst buy ratings supporting potential upside from strategic developments, though fundamental weakness in recent earnings and negative cash flow trends present significant risks. Investors face binary outcomes dependent on MGM deal progression versus underlying business challenges in the media sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

OGN
100% Buy0% Sell
Avg holding period · 0 Days
PPLI
0% Buy100% Sell
Avg holding period · 80 Days

About Organon & Co. Common Stock

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.

Read more on OGN →

About IAC/Interactivecorp

IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.

Read more on PPLI →